Neha Verma1, Amanda L Blackford2, Elissa Thorner3, Jennifer Lehman3, Claire Snyder1,4,5, Vered Stearns3, Karen Lisa Smith6,7. 1. Johns Hopkins Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Division of Biostatistics and Bioinformatics, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. 3. Johns Hopkins Women's Malignancies Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Johns Hopkins Women's Malignancies Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ksmith60@jhmi.edu. 7. Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, First Floor, Building B, 5255 Loughboro Road, NW, Washington, DC, 20016, USA. ksmith60@jhmi.edu.
Abstract
PURPOSE: Sexual function problems are common but under-reported among women receiving adjuvant endocrine therapy for breast cancer. Worsening scores on patient-reported outcomes (PROs) may identify those at risk for sexual function problems during treatment. We performed a secondary analysis of prospectively collected PROs in women receiving adjuvant endocrine therapy to identify factors associated with worsening sexual function. METHODS: Women with stage 0-III breast cancer initiating adjuvant endocrine therapy participating in a prospective cohort completed PROs at baseline, 3, 6, 12, 24, 36, 48, and 60 months. Sexual function was evaluated by the MOS-SP measure. Other measures included PROMIS pain interference, fatigue, depression, anxiety, physical function, and sleep disturbance and the Endocrine Symptom Subscale of the FACT-ES. We evaluated associations between score worsening of at least the minimal important difference (MID) in PROMIS T-scores (4 points) and FACT-ES scores (5 points) with score worsening of at least the MID in MOS-SP scores (8 points) using logistic regression. RESULTS: Among 300 participants, 45.7% experienced ≥ 8-point worsening of MOS-SP score at any time point compared to baseline. Worsening endocrine symptoms (OR 1.34, 95% CI 1.22-1.49, p < 0.001), worsening physical function (OR 1.09, 95% CI 1.00-1.18, p = 0.06), and prior mastectomy (OR 1.45, 95% CI 0.94-2.23, p = 0.09) were associated with MOS-SP score worsening by at least the MID. CONCLUSION: Worsening endocrine symptoms and physical function identified on PROs are associated with worsening sexual function during adjuvant endocrine therapy. Routine assessment of these domains with PROs may identify women at risk for sexual function problems. TRIAL REGISTRATION NUMBER: NCT01937052; Date of Registration: 09/09/2013.
PURPOSE: Sexual function problems are common but under-reported among women receiving adjuvant endocrine therapy for breast cancer. Worsening scores on patient-reported outcomes (PROs) may identify those at risk for sexual function problems during treatment. We performed a secondary analysis of prospectively collected PROs in women receiving adjuvant endocrine therapy to identify factors associated with worsening sexual function. METHODS: Women with stage 0-III breast cancer initiating adjuvant endocrine therapy participating in a prospective cohort completed PROs at baseline, 3, 6, 12, 24, 36, 48, and 60 months. Sexual function was evaluated by the MOS-SP measure. Other measures included PROMIS pain interference, fatigue, depression, anxiety, physical function, and sleep disturbance and the Endocrine Symptom Subscale of the FACT-ES. We evaluated associations between score worsening of at least the minimal important difference (MID) in PROMIS T-scores (4 points) and FACT-ES scores (5 points) with score worsening of at least the MID in MOS-SP scores (8 points) using logistic regression. RESULTS: Among 300 participants, 45.7% experienced ≥ 8-point worsening of MOS-SP score at any time point compared to baseline. Worsening endocrine symptoms (OR 1.34, 95% CI 1.22-1.49, p < 0.001), worsening physical function (OR 1.09, 95% CI 1.00-1.18, p = 0.06), and prior mastectomy (OR 1.45, 95% CI 0.94-2.23, p = 0.09) were associated with MOS-SP score worsening by at least the MID. CONCLUSION: Worsening endocrine symptoms and physical function identified on PROs are associated with worsening sexual function during adjuvant endocrine therapy. Routine assessment of these domains with PROs may identify women at risk for sexual function problems. TRIAL REGISTRATION NUMBER: NCT01937052; Date of Registration: 09/09/2013.
Authors: Leslie R Schover; George P Baum; Lisa A Fuson; Abenaa Brewster; Amal Melhem-Bertrandt Journal: J Sex Med Date: 2014-08-21 Impact factor: 3.802
Authors: Karin Ribi; Weixiu Luo; Barbara A Walley; Harold J Burstein; Jacquie Chirgwin; Rafat H Ansari; Muhammed Salim; Andre van der Westhuizen; Ehtesham Abdi; Prudence A Francis; Stephen Chia; Vernon J Harvey; Anita Giobbie-Hurder; Gini F Fleming; Olivia Pagani; Angelo Di Leo; Marco Colleoni; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Meredith M Regan; Jürg Bernhard Journal: Breast Cancer Res Treat Date: 2020-04-09 Impact factor: 4.872
Authors: Penelope J Robinson; Robin J Bell; Marie K Christakis; Stephanie R Ivezic; Susan R Davis Journal: J Sex Med Date: 2017-10-21 Impact factor: 3.802
Authors: G J van Londen; E B Beckjord; M A Dew; K L Cooper; N E Davidson; D H Bovbjerg; H S Donovan; R C Thurston; J Q Morse; S Nutt; R Rechis Journal: Support Care Cancer Date: 2013-11-24 Impact factor: 3.603
Authors: Anne Oberguggenberger; Caroline Martini; Nathalie Huber; Lesley Fallowfield; Michael Hubalek; Martin Daniaux; Barbara Sperner-Unterweger; Bernhard Holzner; Monika Sztankay; Eva Gamper; Verena Meraner Journal: BMC Cancer Date: 2017-08-30 Impact factor: 4.430